Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13770459 | 0.88 | CYP19A1 (0.47) | MEN1KMT2ACYP19A1NR3C2AR | |
| SCHEMBL13062177 | 0.88 | CYP19A1 (0.47) | MEN1KMT2ACYP19A1NR3C2AR | |
| SCHEMBL13062439 | 0.85 | PGR (0.35) | MEN1KMT2ANR3C2ARPGR | |
| SCHEMBL13062496 | 0.81 | PGR (0.47) | CYP19A1NR3C2ARPGR | |
| SCHEMBL12942727 | 0.79 | PGR (0.39) | ARPGR | |
| SCHEMBL16715970 | 0.79 | AR (0.56) | NR3C2ARPGR | |
| SCHEMBL13062180 | 0.78 | PGR (0.47) | MEN1KMT2AAKR1C3NR3C2AR | |
| SCHEMBL13062168 | 0.78 | PGR (0.36) | MEN1KMT2AAKR1C3ARPGR | |
| SCHEMBL13062179 | 0.76 | AR (0.50) | NR3C2ARPGR | |
| SCHEMBL13062202 | 0.76 | AR (0.54) | NR3C2ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317632-A1 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317632-A1 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | NR5A1, CYP19A1, CYP17A1 | MEN1 618/4885KMT2A 2650/4885CYP19A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.